^
Association details:
| Biomarker: | KMT2A-AFF1 fusion |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Amlexanox Downregulates S100A6 to Sensitize KMT2A/AFF1-Positive Acute Lymphoblastic Leukemia to TNFa Treatment
Excerpt:
In KMT2A/AFF1-positive transgenic (Tg) mice, amlexanox enhanced tumor immunity and lowered the penetrance of leukemia development. Similarly, in a NOD/SCID mouse model of human KMT2A/AFF1-positive ALL, amlexanox broadened GVL responses and extended survival.
DOI:
10.1158/0008-5472.CAN-16-2974